Kodiak Q4 update had ‘a few nice surprises,’ says Capital One

Capital One analyst Zegbeh Jallah says Kodiak Sciences’ (KOD) Q4 earnings and update was "generally in line with expectations, with a few nice surprises." Kodiak affirmed the Q3 readout of four Phase 3 studies evaluating its lead drug Tarcocimab versus Regeneron’s (REGN) Eylea, while also affirming that patient screening is ongoing for a Phase 1 study of its second drug KSI-501, according to Capital One, which contends that "now is a good time to start accumulating shares" with these upcoming milestones and the company having the cash to execute.